trending Market Intelligence /marketintelligence/en/news-insights/trending/_9YgtpATl0cJsvwAR-DiJQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Sandu Pharmaceuticals fiscal Q1 profit climbs 60.1% YOY

The Evolution Of ESG Factors In Credit Risk Assessment: Corporate Governance

Industry Top Trends 2021: Metals and Mining

TMT News & Research: 2020 Recap

Blog

Charter, DIRECTV and Comcast rank as the top 'RSN-friendly' MVPDs


Sandu Pharmaceuticals fiscal Q1 profit climbs 60.1% YOY

Sandu Pharmaceuticals Ltd. said its normalized net income for the fiscal first quarter ended June 30 came to 15 Indian paise per share, a gain of 59.8% from 9 paise per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was 1.0 million rupees, an increase of 60.1% from 651,880 rupees in the prior-year period.

The normalized profit margin increased to 1.2% from 0.8% in the year-earlier period.

Total revenue increased 6.8% year over year to 88.4 million rupees from 82.7 million rupees, and total operating expenses rose 6.5% on an annual basis to 83.6 million rupees from 78.5 million rupees.

Reported net income increased 19.0% year over year to 1.3 million rupees, or 19 paise per share, from 1.1 million rupees, or 16 paise per share.

As of July 15, US$1 was equivalent to 63.50 Indian rupees.